Chemical modification of siRNA

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 2, 2010, Pages 158-167

  Chernolovskaya, Elena L ^a   Zenkova, Marina A ^a  

^a INSTITUTE OF CHEMICAL BIOLOGY AND FUNDAMENTAL MEDICINE   (Russian Federation)

Author keywords

Biodistribution; Chemically modified siRNA; Nnuclease resistance; RNAi; SiRNA; Thermodynamic stability

Indexed keywords

BORANE DERIVATIVE; BORANOPHOSPHATE; DOUBLE STRANDED DNA; NUCLEASE; PHOSPHATE; PHOSPHOROTHIOIC ACID; RIBOSE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

GENE EXPRESSION REGULATION; GENE REPRESSION; GENE SEQUENCE; GENE SILENCING; GENE TARGETING; HUMAN; NONHUMAN; PROTEIN MODIFICATION; PROTEIN RNA BINDING; PROTEIN STABILITY; REVIEW; THERMOSTABILITY;

ANIMALS; ENDONUCLEASES; GENE EXPRESSION REGULATION; GENE SILENCING; HUMANS; MOLECULAR STRUCTURE; NUCLEIC ACID CONFORMATION; RNA INTERFERENCE; RNA, SMALL INTERFERING; THERMODYNAMICS;

EID: 77950836628     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC: Potent and specifc genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 391(6669): 806-811. (Pubitemid 28099681)
2. Carthew RW, Sontheimer EJ: Origins and mechanisms of miRNAs and siRNAs. Cell (2009) 136(4):642-655.
3. Wang Q, Carmichael GG: effects of length and location on the cellular response to double-stranded RNA. Microbiol Mol Biol Rev (2004) 68(3):432-452.
4. Elbashir SM, Harborth MJ, Ledecknel W, Tuschl T: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 411(6836):494-498.
5. Kim DH, Behlke MA, Rose SD, Chang MS, Choi S, Rossi JJ: Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol (2005) 23(2):222-226.
6. Natt F: siRNAs in drug discovery: Target validation and beyond. Curr Opin Mol Ther (2007) 9(3):242-247.
7. Iorns E, Lord CJ, Turner N, Ashworth A: Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov (2007) 6(7):556-568.
8. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J: Interfering with disease: A progress report on siRNA-based therapeutics. Nat Rev Drug Discov (2007) 6(6):443-453.
9. Castanotto D, Rossi JJ: The promises and pitfalls of RNA-interference- based therapeutics. Nature (2009) 457(7228):426-433.
10. Chiu YL, Rana TM: siRNA function in RNAi: A chemical modifcation analysis. RNA (2003) 9(9):1034-1048.
11. Manoharan M: RNA interference and chemically modifed small interfering RNAs. Curr Opin Chem Biol (2004) 8(6): 570-579.
12. Watts JK, Deleavey GF, Damha MJ: Chemically modifed siRNA: Tools and applications. Drug Discov Today (2008) 13(19-20): 842-855.
13. Behlke MA: Chemical modifcation of siRNAs for in vivo use. Oligonucleotides (2008) 18(4):305-320.
14. Terrazas M, Kool ET: RNA major groove modifcations improve siRNA stability and biological activity. Nucleic Acids Res (2009) 37(2):346-353.
15. Czauderna F, Fechtner M, Dames S, Aygun H, Klippel A, Pronk GJ, Giese K, Kaufmann J: Structural variations and stabilising modifcations of synthetic siRNAs in mammalian cells. Nucleic Acids Res (2003) 31(11):2705-2716.
16. De Paula D, Bentley MV, Mahato RI: Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA (2007) 13(4):431-456.
17. Kubo T, Zhelev Z, Ohba H, Bakalova R: Chemically modifed symmetric and asymmetric duplex RNAs: An enhanced stability to nuclease degradation and gene silencing effect. Biochem Biophys Res Commun (2008) 365(1):54-61.
18. Hall AH, Wan J, Shaughnessy EE, Ramsay Shaw B, Alexander KA: RNA interference using boranophosphate siRNAs: Structure-activity relationships. Nucleic Acids Res (2004) 32(20):5991-6000.
19. Bramsen JB, Laursen MB, Nielsen AF, Hansen TB, Bus C, Langkjaer N, Babu BR, Højland T, Abramov M, Van Aerschot A, Odadzic D et al: A large-scale chemical modifcation screen identifes design rules to generate siRNAs with high activity, high stability and low toxicity. Nucleic Acids Res (2009) 37(9):2867-2881.
20. Layzer JM, Mccaffrey AP, Tanner AK, Huang Z, Kay MA, Sullenger BA: In vivo activity of nuclease-resistant siRNAs. RNA (2004) 10(5):766-771.
21. Dowler T, Bergeron D, Tedeschi AL, Paquet L, Ferrari N, Damha MJ: Improvements in siRNA properties mediated by 2′-deoxy-2′-fuoro- β-D-arabinonucleic acid (FANA). Nucleic Acids Res (2006) 34(6):1669-1675.
22. Barik S: Treating respiratory viral diseases with chemically modifed, second generation intranasal siRNAs. Methods Mol Biol (2009) 487:331-341.
23. Collingwood MA, Rose DS, Huang L, Hillier C, Amarzguioui M, Wiiger MT, Soifer HS, Rossi JJ, Behlke MA: Chemical modifcation patterns compatible with high potency dicer-substrate small interfering RNAs. Oligonucleotides (2008) 18(2):187-200.
24. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N et al: Potent and persistent in vivo anti-HBV activity of chemically modifed siRNAs. Nature Biotechnol (2005) 23(8): 1002-1007.
25. Lively TN, Kossen K, Balhorn A, Koya T, Zinnen S, Takeda K, Lucas JJ, Polisky B, Richards IM, Gelfand EW: effect of chemically modifed IL-13 short interfering RNA on development of airway hyperresponsiveness in mice. J Allergy Clin Immunol (2008) 121(1):88-94.
26. Ui-Tei K, Naito Y, Zenno S, Nishi K, Yamato K, Takahashi F, Juni A, Saigo K: Functional dissection of siRNA sequence by systematic DNA substitution: Modifed siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with signifcantly reduced off-target effect. Nucleic Acids Res (2008) 36(7):2136-2151.
27. Zhou C, Liu Y, Andaloussi M, Badgujar N, Plashkevych O, Chattopadhyaya J: Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modifed 2′,4′-carbocyclic-LNAs and-ENAs leads to signifcant modulation of antisense properties. J Org Chem (2009) 74(1):118-134.
28. Jensen TB, Langkjaer N, Wengel J: Unlocked nucleic acid (UNA) and UNA derivatives: Thermal denaturation studies. Nucleic Acids Symp Series (2008) (52):133-134.
29. Fisher M, Abramov M, Van Aerschot A, Xu D, Juliano RL, Herdewijn P: Inhibition of MDR1 expression with altritol-modifed siRNAs. Nucleic Acids Res (2007) 35(4): 41064-41074.
30. Hendrix C, Helmut R, Verheggen I, Van Aerschot A, Seela F, Herdewijn P: 1′,5′-Anhydrohexitol oligonucleotides: Synthesis, base pairing and recognition by regular oligodeoxyribonucleotides and oligoribonucleotides. Chem Eur J (1997) 3(1):110-120.
31. Potenza N, Moggio L, Milano G, Salvatore V, Di Blasio B, Russo S, Messere A: RNA interference in mammalian cells by RNA-3′-PNA chimeras. Int J Mol Sci (2008) 9(3):299-315.
32. Aronin N: Target selectivity in mRNA silencing. Gene Ther (2006) 13(6):509-516.
33. Khvorova A, Reynolds A, Jayasena SD: Functional siRNAs and miRNAs exhibit strand bias. Cell (2003) 115(2):209-216.
34. O'Toole AS, Miller S, Serra MJ: Stability of 3′ double nucleotide overhangs that model the 3′ ends of siRNA. RNA (2005) 11(4):512-516.
35. O'Toole AS, Miller S, Haines N, Zink MC, Serra MJ: Comprehensive thermodynamic analysis of 3′ doublenucleotide overhangs neighboring Watson-Crick terminal base pairs. Nucleic Acids Res (2006) 34(11):3338-3344.
36. Nakano S-I, Uotani Y, Uenishi K, Fujii M, Sugimoto N: Site-selective RNA cleavage by DNA bearing a base pair-mimic nucleoside. J Am Chem Soc (2005) 127(2):518-519.
37. Murao S, Diala I, Fujii M: Suppression of bcr-abl mRNA by chemically modifed siRNA. Nucleic Acids Symp Series (2008) (52):499-500.
38. Zhang N, Tan C, Cai P, Zhang P, Zhao Y, Jiang Y: RNA interference in mammalian cells by siRNAs modifed with morpholino nucleoside analogues. Bioorg Med Chem (2009) 17(6):2441-2446.
39. Bramsen JB, Laursen MB, Damgaard CK, Lena SW, Babu BR, Wengel J, Kjems J: Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res (2007) 35(17):5886-5897.
40. Rose SD, Kim DH, Amarzguioui M, Heidel JD, Collingwood MA, Davis ME, Rossi JJ, Behlke MA: Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res (2005) 33(13):4140-4156.
41. Chu CY, Rana TM: Potent RNAi by short RNA triggers. RNA (2008) 14(9):1714-1719.
42. Samarsky D: Development of novel RNAi therapeutic compounds and in vivo delivery approaches. RNAi Europe, Berlin, Germany (2009) 6.
43. Eder PS, Devine RJ, Dagle JM, Walder JA: Substrate specifcity and kinetics of degradation of antisense oligonucleotides by a 3′ exonuclease in plasma. Antisense Res Dev (1991) 1(2): 141-151.
44. Kennedy S, Wang D, Ruvkun G: A conserved siRNA-degrading RNase negatively regulates RNA interference in C elegans. Nature (2004) 427(6975):645-649.
45. Zou Y, Tiller P, Chen IW, Beverly M, Hochman J: Metabolite identifcation of small interfering RNA duplex by high-resolution accurate mass spectrometry. Rapid Commun Mass Spectrom (2008) 22(12):1871-1881.
46. Haupenthal J, Baehr C, Zeuzem S, Piiper A: Rnase A-like enzymes in serum inhibit the anti-neoplastic activity of siRNA targeting polo-like kinase 1. Int J Cancer (2007) 121(1):206-210.
47. Turner JJ, Jones SW, Moschos SA, Lindsay MA, Gait MJ: MALDI-TOF mass spectral analysis of siRNA degradation in serum confrms an Rnase A-like activity. Mol Biosyst (2007) 3(1):43-50.
48. Volkov AV, Kruglova NS, Meschaninova MI, Venyaminova AG, Zenkova MA, Vlassov VV, Chernolovskaya EL: Selective protection of nuclease-sensitive sites in siRNA prolongs silencing effect. Oligonucleotides (2009) 19(2):191-202.
49. Corey DR: Chemical modifcation: The key to clinical application of RNA interference? J Clin Invest (2007) 117(12):3615-3622.
50. Logashenko EB, Vladimirova AV, Volkov AA, Repkova MN, Ven'yaminova AG, Zenkova MA, Chernolovskaya EL, Vlassov VV: Suppression of MDR1 gene expression by chemically modifed siRNAs. Russ Chem Bull (2006) 55(7):1275-1283.
51. Grünweller A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, Kurreck J: Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res (2003) 31(12):3185-3193.
52. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T: Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J (2001) 20(23):6877-6888.
53. Braasch DA, Jensen S, Liu Y, Kaur K, Arar K, White MA, Corey DR: RNA interference in mammalian cells by chemically-modifed RNA. Biochemistry (2003) 42(26): 7967-7975.
54. Morrissey DV, Blanchard K, Shaw L, Jensen K, Lockridge JA, Dickinson B, McSwiggen JA, Vargeese C, Bowman K, Shaffer CS, Polisky BA et al: Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology (2005) 41(6):1349-1356.
55. Zeng Y, Yi R, Cullen BR: MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci USA (2003) 100(17):9779-9784.
56. Doench JG, Petersen CP, Sharp PA: siRNAs can function as miRNAs. Genes Dev (2003) 17(4):438-442.
57. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 433(7027):769-773.
58. Minks MA, West DK, Benvin S, Baglioni C: Structural requirements of double-stranded RNA for the activation of 2′,5′-oligo(A) polymerase and protein kinase of interferontreated HeLa-cells. J Biol Chem (1979) 254(20):180-183.
59. Robinson M, Judge A, MacLachlan J: siRNA and innate immunity. Oligonucleotides (2009) 19(2):89-101.
60. Hornung V, Guenthner-Biller M, Bourquin C, Ablasser A, Schlee M, Uematsu S, Noronha A, Manoharan M, Akira S, de Fougerolles A, Endres S et al: Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med (2005) 11(3):263-270.
61. Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S et al: 5′-Triphosphate RNA is the ligand for RIG-I. Science (2006) 314(5801):994-997.
62. Schlee M, Hornung V, Hartmann G: siRNA and isRNA: Two edges of one sword. Mol Ther (2006) 14(4):463-470.
63. Marques JT, Williams BR: Activation of the mammalian immune system by siRNAs. Nat Biotechnol (2005) 23(11): 1399-1405.
64. Judge AD, Sood V, Shaw JR, Fang D, Mcclintock K, Maclachlan I: Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol (2005) 23(4):457-462.
65. Kim DH, Longo M, Han Y, Lundberg P, Cantin E, Rossi JJ: Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase. Nat Biotechnol (2004) 22(3):321-325.
66. Reynolds A, Anderson EM, Vermeulen A, Fedorov Y, Robinson K, Leake D, Karpilow J, Marshall WS, Khvorova A: Induction of the interferon response by siRNA is cell type and duplex length-dependent. RNA (2006) 12(6):988-993.
67. Diebold SS, Massacrier C, Akira S, Paturel C, Morel Y, Reis e Sousa C: Nucleic acid agonists for Toll-like receptor 7 are defned by the presence of uridine ribonucleotides. Eur J Immunol (2006) 36(12):3256-3267.
68. Forsbach A, Nemorin JG, Montino C, Müller C, Samulowitz U, Vicari AP, Jurk M, Mutwiri GK, Krieg AM, Lipford GB, Vollmer J: Identifcation of RNA sequence motifs stimulating sequence-specifc TLR8-dependent immune responses. J Immunol (2008) 180(6):3729-3738.
69. Judge A. MacLachlan I: Overcoming the innate immune response to small interfering RNA. Hum Gene Ther (2008) 19(2):111-124.
70. Judge AD, Bola G, Lee AC, Maclachlan I: Design of noninfammatory synthetic siRNA mediating potent gene silencing in vivo. Mol Ther (2006) 13(3):494-505.
71. Cekaite L, Furset G, Hovig E, Sioud M: Gene expression analysis in blood cells in response to unmodifed and 2′-modifed siRNAs reveals TLR-dependent and independent effects. J Mol Biol (2007) 365(1):90-108.
72. Karík K, Buckstein M, Ni H, Weissman D: Suppression of RNA recognition by Toll-like receptors: The impact of nucleoside modifcation and the evolutionary origin of RNA. Immunity (2005) 23(2):165-175.
73. Robbins M, Judge A, Liang L, Mcclintock K, Yaworski E, MacLachlan I: 2′-O-methyl-modifed RNAs act as TLR7 antagonists. Mol Ther (2007) 15(9):1663-1669.
74. Zamanian-Daryoush M, Marques JT, Gantier MP, Behlke MA, John M, Rayman P, Finke J, Williams BR: Determinants of cytokine induction by small interfering RNA in human peripheral blood mononuclear cells. J Interferon Cytokine Res (2008) 28(4):221-233.
75. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, Linsley PS: Expression profling reveals off-target gene regulation by RNAi. Nat Biotechnol (2003) 21(6):635-637.
76. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, Linsley PS: Widespread siRNA 'off-target' transcript silencing mediated by seed region sequence complementarity. RNA (2006) 12(7):1179-1187.
77. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, Baskerville S, Maksimova E, Robinson K, Karpilow J, Marshall WS et al: 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods (2006) 3(3):199-204.
78. Chen P Y, Weinmann L, Gaidatzis D, Pei Y, Zavolan M, Tuschl T, Meister G: Strand-specifc 5′-O-methylation of siRNA duplexes controls guide strand selection and targeting specifcity. RNA (2008) 14(2):263-274.
79. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, Guo J, Johnson JM, Lim L, Karpilow J, Nichols K, Marshall W et al: Position-specifc chemical modifcation of siRNAs reduces 'off-target' transcript silencing. RNA (2006) 12(7): 1197-1205.
80. Gondi CS, Rao JS: Concepts in vivo siRNA delivery for cancer therapy. J Cell Physiol (2009) 220(2):285-291.
81. Takahashi Y, Nishikawa M, Takakura Y: Non-viral vector mediated RNA interference: Its gene-silencing characteristics and factors to achieve RNAi-based gene therapy. Advanced Drug Delivery Rev (2009) 61(9):760-766.
82. Tseng YC, Mozumdar S, Huang L: Lipid based system delivery of siRNA. Advanced Drug Delivery Rev (2009) 61(9):721-731.
83. Lu JJ, Langer R, Chen J: A novel mechanism is involved in cationic lipid-mediated functional siRNA delivery. Mol Pharm (2009) 6(3):763-771.
84. Ohrt T, Schwille P: siRNA modifcations and sub-cellular localization: A question of intracellular transport? Curr Pharm Des (2008) 14(34):3674-3685.
85. Ohrt T, Merkle D, Birkenfeld K, Echeverri CJ, Schwille P: In situ fuorescence analysis demonstrates active siRNA exclusion from the nucleus by Exportin 5. Nucleic Acids Res (2006) 34(5):1369-1380.
86. Viel T, Boisgard R, Kuhnast B, Jego B, Siquier-Pernet K, Hinnen F, Dolle F, Tavitian B: Molecular imaging study on in vivo distribution and pharmacokinetics of modifed small interfering RNAs (siRNAs). Oligonucleotides (2008) 18(3): 201-212.
87. Braasch DA, Paroo Z, Constantinescu A, Ren G, Oz OK, Mason RP, Corey DR: Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett (2004) 14(5):1139-1143.
88. Van De Water FM, Boerman OC, Wouterse AC, Peters JG, Russel FG, Masereeuw R: Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos (2006) 34(8):1393-1397.
89. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME: Impact of tumor-specifc targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA (2007) 104(39):15549-15554.
90. Liu N, Ding H, Vanderheyden JL, Zhu Z, Zhang Y: Radiolabeling small RNA with technetium-99m for visualizing cellular delivery and mouse biodistribution. Nucl Med Biol (2007) 34(4):399-404.
91. Gao S, Dagnaes-Hansen F, Nielsen EJ, Wengel J, Besenbacher F, Howard KA, Kjems J: The effect of chemical modifcation and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther (2009) 17(7):1225-1233.
92. Glud SZ, Bramsen JB, Dagnes-Hansen F, Wengel J, Howard KA, Nyengaard JR, Kjems J: Naked siLNA-mediated gene silencing of lung bronchoepithelium EGFP expression after intravenous administration. Oligonucleotides (2009) 19(2):163-168.
93. Ge Q, Filip L, Bai A, Nguyen T, Eisen HN, Chen J: Inhibition of infuenza virus production in virus-infected mice by RNA interference. Proc Natl Acad Sci USA (2004) 101(23): 8676-8681.
94. Lorenz C, Hadwiger P, John M, Vornlocher HP, Unverzagt C: Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett (2004) 14(19):4975-4977.
95. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J, John M et al: Therapeutic silencing of an endogenous gene by systemic administration of modifed siRNAs. Nature (2004) 432(7014):173-178.
96. Wolfrum C, Shi S, Jayaprakash KN, Jayaraman M, Wang G, Pandey RK, Rajeev KG, Nakayama T, Charrise K, Ndungo EM, Zimmermann T et al: Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol (2007) 25(10):1149-1157.
97. Nishina K, Unno T, Uno Y, Kubodera T, Kanouchi T, Mizusawa H, Yokota T: efficient in vivo delivery of siRNA to the liver by conjugation of α-tocopherol. Mol Ther (2008) 16(4):734-740.
98. Juliano R, Alam MR, Dixit V, Kang H: Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res (2008) 36(12):4158-4171.
99. Endoh T, Ohtsuki T: Cellular siRNA delivery using cell-penetrating peptides modifed for endosomal escape. Advanced Drug Delivery Rev (2009) 61(9):704-709.